|
Accession number;04A0774346
|
| Title;In vitro and in vivo Antifungal Effects of two Fluconazole Intravenous Formulations (Fluconarl 0.2% and Diflucan 0.2%) on Candida albicans |
| Author;
TOKUNAGA TETSUHIRO
(Sawai Pharm. Co., Ltd.)
INOUE TATSUMI
(Nihonseibutsukagakuse Gifuken)
NAKASHIMA HIRONAO
(Nihonseibutsukagakuse Gifuken)
NAKASHIMA CHIYOKO
(Nihonseibutsukagakuse Gifuken)
TSUNODA HIDENOBU
(Nihonseibutsukagakuse Gifuken)
OTSUBO YOSHIKAZU
(Sawai Pharm. Co., Ltd.)
YOKOCHI TAKASHI
(Aichi Medical Univ., School of Medicine, JPN)
|
Journal Title;Japanese Pharmacology & Therapeutics
|
Journal Code:Z0947A
|
ISSN:0386-3603
|
|
VOL.32;NO.9;PAGE.537-541(2004)
|
| Figure&Table&Reference;FIG.3, REF.10 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The present study reports the comparison of antifungal effects between Fluconarl 0.2% and Diflucan 0.2%, fluconazole intravenous formulations. In vitro antifungal activities of Fluconarl 0.2% and Diflucan 0.2% against Candida albicans Fukui strain were determined by a susceptibility test using minimum inhibitory concentration (MIC). The MIC values of Fluconarl 0.2% and Diflucan 0.2% showed no marked difference. In vivo antifungal effects of both formulations were studied on murine experimental model of C. albicans infection. Female ICR mice were inoculated intravenously with 5 * 106 cfu of C. albicans and received treatment of each formulation once a day for consecutive 7 days. The treatment with each formulation at 0.03-0.05 mL body per day improved the survival rates of C. albicans infection compared with untreated control mice. There was no significant difference in the survival rate between Fluconarl 0.2% and Diflucan 0.2%. The present study demonstrated that the therapeutical effect of Fluconarl 0.2% was equivalent to that of Diflucan 0.2% in both in vitro and in vivo experimental systems. (author abst.) |
|
|
|
Related Articles;
|
